Teclistamab - Genmab/Janssen Research & Development
Alternative Names: BCMAxCD3 - Genmab/Janssen Research & Development; JNJ 7957; JNJ-64007957; Tebbei; tecbeili; Techbayri; Techvaili; teclistamab-cqyv; Tecvaili; TECVAYLI; TekbeiriLatest Information Update: 12 Nov 2026
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Genmab; Janssen Research & Development; Johnson & Johnson
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Yes - Multiple myeloma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
Most Recent Events
- 12 Nov 2026 Janssen Research & Development initiates enrolment in the phase III MajesTEC-4 trial in Multiple myeloma in Argentina, China, Poland, Portugal (SC) (NCT05243797)
- 21 Sep 2026 CHMP recommends approval for teclistamab for Multiple myeloma (Second-line therapy or greater, Monotherapy) in European Union
- 22 Aug 2026 Launched for Multiple myeloma (Combination therapy, Second-line therapy or greater) in France, Denmark, Belgium, Austria, Spain, Portugal, Hungary, Finland, Sweden, Netherlands, Ireland (SC)